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Abstract
Background: In previously published studies, oncolytic adenovirus-mediated gene therapy has produced good
results in targeting cancer cells. However, safety and efficacy, the two most important aspects in cancer therapy,
remain serious challenges. The specific expression or deletion of replication related genes in an adenovirus has
been frequently utilized to regulate the cancer cell specificity of a virus. Accordingly, in this study, we deleted
24 bp in E1A (bp924-bp947) and the entirety of E1B, including those genes encoding E1B 55kDa and E1B19kDa.
We used the survivin promoter (SP) to control E1A in order to construct a new adenovirus vector named Ad.SP.
E1A(Δ24).ΔE1B (briefly Ad.SPDD). HCCS1 (hepatocellular carcinoma suppressor 1) is a novel tumor suppressor gene
that is able to specifically induce apoptosis in cancer cells. The expression cassette AFP-HCCS1-WPRE-SV40 was
inserted into Ad.SPDD to form Ad.SPDD-HCCS1, enabling us to improve the safety and efficacy of oncolytic-
mediated gene therapy for liver cancer.
Results: Ad.SPDD showed a decreased viral yield and less toxicity in normal cells but enhanced toxicity in liver
cancer cells, compared with the cancer-specific adenovirus ZD55 (E1B55K deletion). Ad.SPDD-HCCS1 exhibited a
potent anti-liver-cancer ability and decreased toxicity in vitro. Ad.SPDD-HCCS1 also showed a measurable capacity
to inhibit Huh-7 xenograft tumor growth on nude mice. The underlying mechanism of Ad.SPDD-HCCS1-induced
liver cancer cell death was found to be via the mitochondrial apoptosis pathway.
Conclusions: These results demonstrate that Ad.SPDD-HCCS1 was able to elicit reduced toxicity and enhanced
efficacy both in vitro and in vivo compared to a previously constructed oncolytic adenovirus. Ad.SPDD-HCCS1
could be a promising candidate for liver cancer therapy.
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Background
Liver cancer is one of the most common malignant
tumors worldwide and the third leading cause of cancer-
related death. Because of its high malignancy and fast
progression, most patients with high-grade cancers have
tumors that are unresectable. To date, no remedy has
shown efficacy in these patients [1,2]. It is important that
we develop an efficient and safe drug for patients with
liver cancer.
The strategy of “Cancer Targeting Gene-Viro-Therapy”
(CTGVT), was developed in 2001 [3] and has shown
promise in the treatment of cancer. It combines the
advantages of gene therapy and oncolytic viral therapy.
Oncolytic adenoviruses can replicate themselves in
cancer cells and lyse the carcinoma, but very inefficient
in normal cells. Tumor suppressor genes can replicate
together with oncolytic viral vectors, thereby greatly
enhancing the ability to induce cancer cell death [4]. The
advantage of this combination is to enable the oncolytic
adenovirus to harbor antitumor genes, thereby facilitating
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them to specifically and efficiently kill cancer cells. Can-
cer Targeting Dual Gene-Viro-Therapy (CTGVT-DG)
with a combination of two viruses carrying compensatory
or synergetic genes has shown near eradication of tumors
in nude mice [5-7]. Cancer Targeting Gene-Viro-Therapy
Specific for Liver Cancer (CTGVT-LC) is a modification
of CTGVT that can specifically target liver cancer. It is
predicted that excellent antitumor drugs will arise from
CTGVT and its modifications but are unlikely to result
from gene or viral therapy alone [8].
Adenoviruses have been modified in various ways to
improve their specificity in cancer cells. In such viruses,
E1A, an early adenovirus gene, is controlled by cancer
specific promoters, such as the survivin promoter [9], to
regulate specific replication of adenoviruses. The CR2
domain of E1A (bp924- bp947) is known to interact with
the Rb protein, repressing Rb activation and increasing
the replication of the adenovirus. Deletion of this 24 bp
domain results in the adenovirus selectively targeting var-
ious cancer cells with dysfunction of the Rb pathway
[10,11]. The E1B 55kDa gene has been deleted to form
the cancer-specific adenovirus ONYX-015 [12]. It is now
believed that E1B 55kDa functions as a result of late viral
RNA export rather than p53 inactivation, as was pre-
viously believed [13]. Heat shock can cause phenocopy of
E1B 55KDa late function in most cancer cells [14]. How-
ever, when an adenovirus is modified, its anti-tumor effi-
cacy is usually reduced. The E1B 19kDa protein was
deleted in previous studies to enhance the anti-tumor
efficacy of an adenovirus, specifically its ability to inhibit
cell apoptosis by blocking the function of the proapopto-
tic proteins Bax, Bak, p53 and TNF [15].
a-fetoprotein (AFP) is an established marker of liver
cancer, and it is present at increased levels in the serum
of approximately 75% of all liver cancer patients [16].
The high levels of AFP are an indication of the specific
activity of the AFP promoter in liver cancer, and it may
be used to improve the safety of gene therapy in AFP
positive liver cancer cells. AFP promoter was used to
control the anti-tumor gene cytosine deaminase and
cytosine deaminase specially expressed in liver cancer
cells [17]. The adenovirus with the key replicative gene
E1A under the control of AFP promoter can specially
replicate in AFP positive liver cancer cell lines [18,19].
All this indicates that AFP promoter as a potential regu-
latory element in liver cancer therapy.
HCCS1 was discovered as a liver cancer specific tumor
suppressor gene that is frequently mutated in liver cancer
[20,21]. A previously constructed oncolytic adenovirus,
ZD55-HCCS1, has been shown to elicit strong anti-tumor
efficacy [22]. WPRE (Woodchuck Hepatitis Virus Post-
transcriptional Regulatory Element) is a cis-acting RNA
element that is capable of increasing the expression of
genes located upstream [23] and can be used in various
kinds of vectors to promote gene expression [24].
In this study, we constructed a new oncolytic adenovirus
vector by deleting 24 bp of E1A, as well as the genes
encoding E1B 55kDa and E1B 19kDa. We also utilized a
survivin promoter(denoted as SP) to control E1A, and
named it as Ad.SP.E1A(Δ24).ΔE1B (also denoted Ad.
SPDD). This quadruple-regulated adenovirus, Ad.SPDD,
exhibited improved safety and enhanced efficacy com-
pared with ZD55 (similar to ONYX-015), an adenovirus
with an E1B 55kD deletion that was previously developed
in our laboratory showing capacity to target cancer cells
[4-7,25,26]. Moreover, this adenovirus with complete E1B
deletion permits the insertion of large gene expression
cassettes.
To enhance both anti-tumor efficacy and specificity, the
HCCS1 expression cassette AFP-HCCS1-WPRE-SV40 was
introduced into the vector Ad.SP.E1A(Δ24).ΔE1B to pro-
duce Ad.(AFP-HCCS1-WPRE)SP.E1A(Δ24).ΔE1B (also
denoted Ad.SPDD-HCCS1). Additionally, owing to the
lack of a commercial primary antibody specific for
HCCS1, another adenovirus, Ad.SPDD-HCCS1HA, in
which HCCS1 is fused to an HA tag named HCCS1HA,
was developed at the same time to detect the expression
of the HCCS1 protein. Ad.SPDD-HCCS1 showed a potent
anti-tumor effect specific for liver cancer in both in vitro
and in vivo experiments, with induction of the mitochon-
drial apoptosis pathway as its underlying mechanism. Our
CTGVT-LC strategy using Ad.SPDD-HCCS1 may be a
promising therapy for selectively targeting liver cancer.
Results
Liver cancer-specific transcriptional activity of the AFP
promoter
The transcriptional activity of the commercialized
SV40EAFP in different cell lines was detected using a luci-
ferase reporter assay. In addition to being present in three
normal cell lines, SV40EAFP activity was observed in four
AFP positive and two AFP negative liver cancer cell lines.
As shown in Figure 1A, the SV40EAFP promoter exhib-
ited 33%-123% as high activity as the pGL3-control in the
AFP positive cell lines Hep3B, Huh-6, HepG2 and Huh-7,
whereas this activity was only 1%-4% as high in the AFP
negative cell lines BEL7404 and SMMC7721, as well as in
the normal cell lines MRC-5, QSG7701 and L-02. These
results suggested that SV40EAFP was especially active in
AFP positive liver cancer cell lines.
Virus construction and characterization
The quadruple-regulated adenoviruses Ad.SPDD, Ad.
SPDD-HCCS1, and Ad.SPDD-HCCS1HA were con-
structed as shown in Figure 1B. Virus identification utiliz-
ing PCR amplification and sequencing of the PCR
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Figure 1 Construction and characterization of viruses. (A) Transcriptional activity of the AFP promoter in different cell lines. The AFP
promoter with an SV40 enhancer was incorporated into pGL3-basic. The relative activity of pGL3-SV40EAFP to pGL3-Control in various cell lines
are presented as the mean+SD (n = 3). (B) Schematic structure of the viruses Ad.SPDD, Ad.SPDD-HCCS1, and Ad.SPDD-HCCS1. ITR, inverted
terminal repeat; ψ, viral packing signal. Ad.SPDD was quadruply modified compared to the wild-type adenovirus; the modifications were the
deletion of E1B19K, the deletion of E1B55K, and the deletion of 24 bp of E1A, as well as deletion of the survivin promoter controlling E1A
expression. HCCS1 or HA-tagged HCCS1 in a cassette was carried by Ad.SPDD. (C) Characterization of viruses by western blot analysis. Huh-7 cells
were infected with the indicated viruses, and the levels of the expressed E1A, E1B 19KDa, E1B 55KDa and HA-Tag were analyzed 48 hours post
infection (h.p.i), with actin as loading control. (***: P < 0.001).
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products of E1A confirmed the insertion of the gene
expression cassettes and the deletion of 24 bp of E1A, as
well as that the virus stocks were free of wild-type adeno-
virus contamination (Additional file 1). Western blotting
was also performed to detect adenovirus gene expression
in Huh-7 cells (Figure 1C). All viruses expressed E1A,
whereas all viruses except for the wild-type adenovirus
(Ad.WT) failed to express E1B 19KDa and E1B 55KDa.
Anti-HA antibody detection revealed the expression
of HCCS1, which was observed only for Ad.SPDD-
HCCS1HA. The HCCS1HA gene was expressed at parti-
cularly high levels in Huh-7 cells, as observed via
the detection of HA tag-specific antibody expressed in Ad.
SPDD-HCCS1HA-infected MRC-5 and Huh-7 cells (Addi-
tional file 2).
Ad.SPDD exhibited less toxicity and an enhanced ability
to lyse cancer cells than ZD55
The levels of E1A expressed by Ad.SPDD, ZD55, and Ad.
WT in MRC-5 and Huh-7 cells were detected by western
blot analysis. The expression of E1A by ZD55 and Ad.WT
in MRC-5 cells was strong, although only traces of E1A
were observed to be expressed by Ad.SPDD. However,
there was no significant difference in E1A expression by
Ad.SPDD, ZD55 and Ad.WT in Huh-7 cells, indicating
that the survivin promoter can specifically control the
expression of E1A by Ad.SPDD in cancer cells (Figure 2A).
The replicative ability of Ad.SPDD, ZD55, and Ad.WT
in both normal and cancer cell lines was tested. Ad.SPDD
replicated nearly as efficiently as ZD55 and Ad.WT in
Huh-7 and Hep3B cells, but its replication was weaker in
MRC-5 cells (Figure 2B, Additional file 3). In MRC-5 and
Huh-7 cells, the adenovirus titer at 8 hours after infection
was used as negative control, and it showed very low titer
compared to the titer at 48 hours post infection (Figure
2C). A cell viability assay was performed to examine the
cytotoxicity of Ad.SPDD and ZD55 on MRC-5 and Huh-7
cells. Ad.SPDD showed lower toxicity than did ZD55 on
MRC-5 cells at an MOI of 50, whereas it exhibited higher
cytotoxicity than ZD55 on Huh-7 cells at an MOI of 5
(Figure 2D). These results demonstrated the reduced toxi-
city and enhanced efficacy associated with the quadruple-
regulated adenovirus Ad.SPDD compared with ZD55.
Ad.SPDD-HCCS1 specifically targeted liver cancer in vitro
The cytotoxicity of the viruses against both normal and
cancer cell lines was evaluated by a crystal violet staining
assay and an MTT assay. As shown in Figure 3A, the
cytopathic effects of Ad.SPDD-HCCS1 and Ad.SPDD-
HCCS1HA were equal to that of ZD55-HCCS1 in the
AFP positive liver cancer cell lines Huh-7 and HepG2.
The cytopathic effects were lower in the AFP-negative
cancer cell lines 786-O, A549, and the normal cell line
MRC-5, as expected. This finding suggests that Ad.
SPDD-HCCS1 possesses a higher specificity for AFP
positive liver cancer than does ZD55-HCCS1. Cell viabi-
lity was measured either 4 days after viral infection
at different MOIs (Figure 3B) or was detected each day
till the 4th day after a viral infection at an MOI of 10
(Figure 3C). The Ad.SPDD-HCCS1 and Ad.SPDD-
HCCS1HA showed potent cytotoxicity against Huh-7
cells, similar to ZD55-HCCS1, and elicited time-depen-
dent and dose-dependent effect. However, both the ade-
noviruses showed little cytotoxicity on MRC-5 cells.
Notably, both in the crystal violet staining assay and the
MTT assay, ZD55-HCCS1 damaged the normal cell line
MRC-5 to some extent after infection at an MOI of 10,
indicating a potential safety hazard with clinical use at
high doses. However, Ad.SPDD-HCCS1 had no observa-
ble cytotoxic effect even at an MOI of 100.
Antitumor efficacy of Ad.SPDD-HCCS1 on tumor
xenografts
In addition to its liver cancer-specific cytotoxicity in vitro,
the antitumor efficacy of the new construct was also evalu-
ated in vivo on Huh-7 tumor xenografts that had been
established in nude mice. These tumors had a high degree
of malignancy and grew rapidly. In the PBS group, most
mice either had tumor sizes of more than 2000 mm3 or
died within 2 months. At the end of the experiment, only
one nude mouse remained in the PBS group, and this
mouse was very weak. However, the nude mice in the Ad.
SPDD, Ad.SPDD-HCCS1 and Ad.SPDD-HCCS1HA
groups were all alive. The mean tumor volume of the Ad.
SPDD, Ad.SPDD-HCCS1 and Ad.SPDD-HCCS1HA
groups was 835.93 mm3, 272.60 mm3 and 436.99 mm3,
respectively (Figures 4A and 4B), indicating that our newly
designed Ad.SPDD-HCCS1 and Ad.SPDD-HCCS1HA
constructs were able to strongly inhibit liver cancer
growth.
To further determine whether the gene or virus can effi-
ciently exist in the tumor tissue and induce tumor sup-
pression, tumor sections from the Ad.SPDD-, Ad.SPDD-
HCCS1- and Ad.SPDD-HCCS1HA-treated mice were
stained with hematoxylin and eosin (H&E) and analyzed.
As shown in Figure 4C, there were large necrotic regions
in the tumor sections from Ad.SPDD-HCCS1- and Ad.
SPDD-HCCS1HA-treated mice. Smaller necrotic areas
were also observed in the tumor sections from Ad.SPDD-
treated mice. We examined the expression of the adeno-
virus capsid protein hexon and HCCS1 (via an HA-tag-
specific antibody) by immunohistochemical staining, and
we found significant positive staining by hexon-specific
antibody in the adenoviruses treated groups, but only Ad.
SPDD-HCCS1HA infected tumor shows positive staining
by HA tag-specific antibody (Figure 4C). Compared with
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the negative result in the PBS group, both the viral replica-
tion and HCCS1 expression in the tumor xenograft sug-
gested that the efficacy of tumor suppression may have
resulted from the function of both the virus and the
expressed gene.
Ad.SPDD-HCCS1 induced apoptosis of liver cancer cells
both in vitro and in vivo
Because Ad.SPDD-HCCS1 effectively inhibited tumor
growth, several assays were performed to investigate the
underlying mechanism. As shown in Figure 5A, infection
with Ad.SPDD-HCCS1 apparently caused nuclear frag-
mentation and chromatin condensation in the Huh-7
cells. When the virus-infected tumor cells were subjected
to flow cytometric assay after Annexin V-FITC/PI
staining, we found that the percentage of Annexin-V posi-
tive cells in the Ad.SPDD-HCCS1- or Ad.SPDD-
HCCS1HA-infected cell samples was similar to that in the
ZD55-HCCS1-infected cell sample, and all of these cell
samples had a higher percentage of Annexin-V positive
cells than the mock- and Ad.SPDD- infected cell samples
(Figure 5B). In addition to this in vitro test, virus-treated
tumor xenografts were sectioned and analyzed for apopto-
sis. TUNEL analysis revealed that Ad.SPDD-HCCS1 and
Ad.SPDD-HCCS1HA each elicited profound apoptosis in
the tumors (Figure 5C), whereas no apoptosis was
observed in sections from PBS-treated mice. Taken
together, the results showed that the anti-tumor character-
istics of the virus resulted partly from its induction of
apoptosis.
Figure 2 Ad.SPDD shows less toxicity and an enhanced efficacy at lysing cancer cells compared to ZD55. (A) Specific expression of E1A
in Huh-7 cells infected with Ad.SPDD. MRC-5 and Huh-7 cells were infected with Ad.SPDD, ZD55 and Ad.WT or without any infection, and the
expression of E1A was detected 48 hours post infection, with actin used as loading control. (B) The replicative ability of the adenoviruses in
MRC-5 and Huh-7 cells. MRC-5 and Huh-7 cells were infected at an MOI of 10, and the adenovirus titer was measured 48 hours after infection.
The results are presented as the mean+SD (n = 3). (C) The adenovirus titer 8 hours after adenovirus infection of MRC-5 and Huh-7 cells. The
adenovirus titers in the MRC-5 and Huh-7 cells were measured 8 hours after infection with the indicated adenovirus at an MOI of 10. (D) Ad.
SPDD showed improved cancer specificity over ZD55. MRC-5 and Huh-7 cells were infected with Ad.SPDD and ZD55 at the indicated MOIs. Cell
viability was measured 4 days post infection. The results are presented as the mean+SD (n = 6). * indicates P < 0.05, *** indicates P < 0.001, and
NS means not significant (with a P value > 0.05).
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Figure 3 Ad.SPDD-HCCS1 has specific anti-liver-cancer activity in vitro. (A) Crystal violet staining was performed on both tumor and normal
cells that had been infected with adenovirus at the indicated MOIs. AFP positive cancer cells (Huh-7 and Hep3B), AFP negative cancer cells (786-
O and A549) and AFP negative normal cells (MRC-5) were infected with various adenoviruses at an MOI of 0.1, 1, 10, and 100. Crystal violet
staining was performed 4 days after infection. (B) Viability of the MRC-5 and Huh-7 cells infected at various viral MOIs on the 4th day. (C) Viability
of MRC-5 and Huh-7 cells infected at an MOI of 10 at the indicated time. The cells were infected with different viruses and were measured from
days 1 to 4. Results are presented as the mean ± SD for 6 repeated wells. A P value < 0.05 or < 0.01 is indicated as * or **, respectively.
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Ad.SPDD-HCCS1 induced apoptosis of liver cancer cells
via the mitochondrial/caspase-9/caspase-3 pathway
To further understand the mechanism by which Ad.
SPDD-HCCS1 caused apoptosis of liver cancer cells, we
evaluated the key apoptosis-related proteins caspase-3,
caspase-8 and caspase-9. As shown in Figure 6A, the pre-
cursors of caspase-3 and caspase-9 were present in
decreased amounts, indicating the activation of caspase-3
and caspase-9, 48 hours after viral infection of Huh-7 cells
compared with before viral infection. Little difference in
the amount of the caspase-8 precursor that was present
was shown even 96 hours post virus treatment compared
with before viral infection, indicating that the apoptosis
induced by Ad.SPDD-HCCS1 may occur via the mito-
chondrial pathway. We further tested the changes in the
mitochondrial membrane potential, Δψm, of the virus-
infected cells with a JC-1 probe. A marked increase in JC-
1 monomers was found in Ad.SPDD-HCCS1- and Ad.
Figure 4 Antitumor efficacy of viruses on Huh-7 tumor xenografts in nude mice. (A) Ad.SPDD-HCCS1 and Ad.SPDD-HCCS1HA suppress the
growth of Huh-7 tumors in vivo. The tumor volumes (mean+SD, n = 6) were measured and estimated every four days. (B) The ratios of
surviving mice during the observation period in groups treated with different adenoviruses. (C) H&E staining and immunohistochemical staining
of tumor sections using anti-hexon and anti-HA tag antibodies. Representative images are shown at 400 × magnification for the different
samples Scale bar = 100 μm. (*: P < 0.05).
Xu et al. Molecular Cancer 2011, 10:133
http://www.molecular-cancer.com/content/10/1/133
Page 7 of 14
Figure 5 Ad.SPDD-HCCS1 can induce apoptosis of hepatocellular carcinoma cells both in vitro and in vivo. (A) Ad.SPDD-HCCS1 and Ad.
SPDD-HCCS1HA induce more nuclear condensation than Ad.SPDD. Hoechst33258 staining was performed on Huh-7 cells 48 hours after infection
with viruses at an MOI of 10. Scale bar = 20 μm. (B) Annexin V-FITC/PI staining FACS assay. The percentages of the cells in the second and
fourth quadrants are shown. (C) Detection of apoptosis in tumor sections by TUNEL staining. Scale bar = 100 μm.
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Figure 6 Ad.SPDD-HCCS1 induces mitochondrial-mediated apoptosis in liver cancer cells. (A) Western blot analysis of apoptosis-related
proteins in Huh-7 cells infected with Ad.SPDD, Ad.SPDD-HCCS1 or Ad.SPDD-HCCS1HA. Actin was used as a loading control. (B) Ad.SPDD-HCCS1
and Ad.SPDD-HCCS1HA induced an increased loss of mitochondrial membrane potential in Huh-7 cells. The mitochondrial membrane potentials
of the Huh-7 cells infected with the indicated viruses were analyzed by JC-1 staining via FACS detection. The percentage of cells in the
trapeziform region is shown as cells with lost mitochondrial membrane potential.
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SPDD-HCCS1HA- treated Huh-7 cells, indicating a drop
in Δψm, but not in Ad.SPDD-infected Huh-7 cells (Figure
6B). These results suggested that Ad.SPDD-HCCS1
induced the apoptosis of liver cancer cells via the mito-
chondrial pathway.
Discussion
In this study, we successfully constructed a quadruple-
regulated adenovirus named Ad.SPDD-HCCS1 with spe-
cificity for liver cancer cells. This adenovirus was gener-
ated with the following: the survivin promoter (SP)
driving the E1A gene; the deletion of both of the Rb
binding domains of E1A; the whole of E1B, including the
genes encoding E1B-19K and E1B-55K; and the liver
cancer-specific expression cassette AFP-HCCS1-WPRE-
SV40, which was inserted upstream of E1A. Although a
dual- or triple-regulated vector was studied in previous
studies, to our knowledge no quadruple-regulated adeno-
viral vectors have previously been reported.
It is well known that modifying an adenovirus to
improve its specificity usually reduces the replication
capacity of the adenovirus while lowering its antitumor
efficacy. It is important to achieve an effective balance
between safety and efficacy when designing an adeno-
virus to target liver cancer. The quadruple-regulated
adenovirus Ad.SPDD satisfied both specificity and effi-
cacy. It showed improved replication in cancer cells and
enhanced antitumor effects on Huh-7 cells compared to
ZD55, along with a much lower toxicity than ZD55
against the normal cell line MRC-5 according to the
MTT assay. The reduced toxicity might result in a bet-
ter safety profile in vivo. Moreover, the complete dele-
tion of E1B in Ad.SPDD allowed space for the insertion
of an expression cassette with large genes.
The cytotoxicity and anti-tumor capacity of Ad.SPDD-
HCCS1 were detected in vitro and in vivo, respectively;
its anti-liver-cancer activity was as good as that of ZD55-
HCCS1. More significantly, Ad.SPDD-HCCS1 exhibited
decreased toxicity than ZD55-HCCS1, as shown by both
a crystal violet staining assay and an MTT assay, suggest-
ing that Ad.SPDD-HCCS1 is a significantly better con-
struct than ZD55-HCCS1 for liver cancer targeting. In
the Figure 3C it seems that the Ad.SPDD-HCCS1 and
Ad.SPDD-HCCS1HA elicited similar effect as the Ad.
SPDD, although indeed they showed significant differ-
ence, with the P value smaller than 0.001. However, in
Figure 3B, Huh-7 cells infected with Ad.SPDD-HCCS1,
Ad.SPDD-HCCS1HA at an MOI of 100 showed a lot of
difference with Ad.SPDD. This is due to the dose-depen-
dent effect of the adenoviruses, the HCCS1 gene carried
by adenovirus exhibited its function in the condition of
sufficient expression.
The AFP promoter was used in this work to drive
HCCS1 to improve its safety. As many patients with
liver carcinoma have liver cirrhosis, but not normal
liver, and some liver cirrhosis are AFP positive. Yao F et
al. found that the percentage of AFP positive samples in
patients with liver cirrhosis is smaller than that with
liver cancer, and the AFP mRNA in samples of liver
cirrhosis is lower than that of liver cancer [27]. This
indicated the special AFP promoter activity in liver can-
cer cells, though with slight activity in cirrhosis. Otsuru
A et al. found that in liver cirrhosis sections only a
small number of cells showed positive hybridization by
in situ hybridization analysis of AFP mRNA, but the
majority of tumor cells showed positive hybridization
[28]. This indicates that AFP promoter may be a specific
anti-liver-cancer cell promoter, and combines it with
other safety regulatory element will possibly improve its
safety further.
In the Ad.SPDD-HCCS1 or Ad.SPDD-HCCS1HA,
there are two promoters, survivin promoter driving E1A
and AFP promoter driving HCCS1 or HCCS1HA, in the
adjacent region, it is possible that they may cis activate
each other with the enhancers. However, in Ad.SPDD,
the survivin promoter used is just 269 bp, a very short
promoter, and it possesses essential sites for binding
transcription factors [29]. It should not affect the AFP
promoter. As to the enhancer on the AFP promoter’s
effect on survivin promoter, Figure 3B and 3C preclude
this possibility. Ad.SPDD-HCCS1 or Ad.SPDD-
HCCS1HA didn’t show any enhanced cytoxicity on
MRC-5 compared to Ad.SPDD. This indicated two issue,
one is that HCCS1 is specially expressed in the Huh-7
cells, which is demonstrated by additional file 2 and
another one is that the AFP-HCCS1-SV40 cassette didn’t
enhance the cytotoxicity of the vector adenovirus Ad.
SPDD, indicating that the survivin promoter activity is
not elevated in MRC-5 by AFP promoter. In the hypoth-
esis that the survivin promoter is enhanced by the AFP
promoter, Ad.SPDD-HCCS1 or Ad.SPDD-HCCS1HA
will show more cytoxicity on MRC-5 than Ad.SPDD due
to the elevated replicative ability in MRC-5, but this is
opposite to the shown results.
Ad.SPDD-HCCS1 may specifically inhibit liver cancer in
two ways. First, the adenovirus replicated in the liver can-
cer cells caused lysis. Second, the amplification of the
tumor suppressor gene HCCS1 was accompanied by repli-
cation of the oncolytic adenoviral vector, while it also
induced apoptosis through the mitochondrial/caspase-9/
caspase-3 pathway.
The mechanism by which Ad.SPDD-HCCS1 kills liver
cancer cells was demonstrated to be mitochondria-trig-
gered apoptosis. Despite detecting apoptosis both in vitro
and in vivo, the level of ATP in the infected cells increased.
This is not consistent with the phenomenon of apoptosis,
in which the cellular ATP level decreases. It is known that,
of the three main types of programmed cell death, only
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autophagy leads to an increase in cellular ATP levels. It has
been reported that autophagy occurs in the progression of
adenoviral infection of cells. Therefore, we proposed that
autophagy might have contributed to the inhibitory effect
of Ad.SPDD-HCCS1on liver cancer cells. To test this
hypothesis, we co-infected Huh-7 cells with an LC3-EGFP
plasmid and Ad.SPDD-HCCS1, but no punctate fluores-
cence was observed (data not shown). In addition, the
apoptosis rate measured by the Annexin V-FITC/PI flow
cytometric assay and the death rate measured by the MTT
cell viability test were similar (approximately 30 percent).
Thus, we cannot confirm the involvement of autophagy in
this phenomenon, although we speculate that necrosis-like
cell death, as reported by Abou El Hassan MA [30], may
be occurring. Some non-classical programmed cell death
phenomena may also have occurred as a result of viral
replication and transgene expression. Because Ad.SPDD-
HCCS1 treatment increased the total ATP level without
altering the rate of cell death, it is possible that viral repli-
cation plays a role.
Ad.SPDD-HCCS1 showed a potent and specific anti-
liver cancer efficacy. As such, we believe that Ad.SPDD-
HCCS1 could bee a promising candidate for the treat-
ment of AFP positive liver cancer.
Conclusions
Quadruple-regulated adenoviruses carrying an AFP pro-
moter-controlled HCCS1 gene showed reduced toxicity
and excellent anti-liver cancer efficacy in this study. The
adenoviral vector Ad.SPDD had less toxicity and more
efficacy than the previously constructed cancer-specific
adenovirus ZD55. The gene-armed oncolytic adenovirus
Ad.SPDD-HCCS1 exhibited liver-cancer specificity and
observable anti-liver-cancer capacity both in vitro and in
vivo. This work provides a feasibility study for generating
effective cancer specificity and anti-cancer efficacy by
using an adenoviral vector with a combination of modifi-
cations. Using the Ad.SPDD-HCCS1 construct seems to
be a promising strategy for future clinical application in
liver cancer therapy.
Methods
Cell lines and cell culture
The human liver cancer cell lines Huh-7 and Huh-6 were
obtained from the RIKEN Cell Bank (Ibaraki, Japan). The
human liver cancer cell lines HepG2, Hep3B and
BEL7404; the human colorectal cancer cell line SW620;
the human renal carcinoma cell line 786-O; the human
normal liver cell lines L-02 and QSG-7701; and the
human lung fibroblast cell line MRC-5 were purchased
from the Cell Bank of the Type Culture Collection of the
Chinese Academy of Sciences (Shanghai, China). The
human embryonic kidney 293 cell line (HEK293) was
obtained from Microbix Biosystems Inc. (Toronto,
Ontario, Canada). All cell lines were cultured according to
the instructions of the corresponding providers.
Luciferase Reporter Assay
The pGL3-Basic and pGL3-Control reporter plasmids
were purchased from Promega (Madison, WI), whereas
the pCMV-b-gal normalization plasmid was obtained
from Invitrogen (Carlsbad, CA). The AFP promoter with
an SV40 enhancer, SV40EAFP, was purchased from Invi-
vogen (San Diego, CA) and cloned into pGL3-Basic to
form the reporter plasmid pGL3-SV40EAFP. Cells were
seeded in 24-well plates at 80% confluence and transfected
with reporter plasmids and pCMV-b-gal using Lipofecta-
mine 2000 (Invitrogen). Cells were harvested 48 hours
later, and the luciferase activity was detected using the
Luciferase Assay System (Promega).
Plasmid and virus construction
The adenoviral packaging vector pBHGE3 was obtained
from Microbix Biosystem Inc. The adenoviral shuttle vec-
tors pCA13Δ, pAd.surP-E1AΔ24, and pAd.AFP-E1A-
ΔE1B had previously been constructed by our group pAd.
surP-E1AΔ24 and pAd.AFP-E1A-ΔE1B were digested with
EcoRI and XbaI, respectively, to obtain surP-E1AΔ24 and
pAd. ΔE1B, respectively. These were ligated to form pAd.
SP. ΔE1B. The promoters SV40EAFP and WPRE were
inserted into pCA13Δ by using the restriction enzymes Sal
I and BamHI, respectively. HCCS1 was amplified by PCR
using forward (5’-CGGGAATTCATGATGGAGGAG-
GAGGAA-3’) and reverse (5’-TTAGGATCCCTCGAGC-
TACGTCCATCTCACCTG-3’) primers. HCCS1HA was
amplified by PCR using forward (5’-CGGGAATTCATG
ATGGAGGAGGAGGAA-3’) and reverse (5’-TTACTC-
GAGTTATCAGGCGTAGTCGGGACGTCGTAGGGG-
TAC- GTCC ATCTCACCTGTTC -3’) primers, with
ZD55-HCCS1 as the template. The PCR products were
digested with EcoRI and XhoI and cloned into pCA13-
AFP-WPRE to construct pCA13-HCCS1 and pCA13-
HCCS1HA. The HCCS1 and HCCS1HA expression cas-
settes were released and introduced into pAd.SPDD to
produce pAd.SPDD-HCCS1 and pAd.SPDD-HCCS1HA.
The adenoviruses Ad.SPDD, Ad.SPDD-HCCS1 and Ad.SP.
DD-HCCS1HA were generated by homologous recombi-
nation between the corresponding plasmid and pBHGE3
in the HEK293 cells, using the Effectene Transfection
Reagent (Qiagen, Germany) as the transfection reagent.
The viruses were amplified in HEK293 cells and purified
by ultracentrifugation in a cesium chloride gradient. The
titers of the viruses were measured in HEK293 cells.
Adenovirus replication assay in vitro
MRC-5, Huh-7 and Hep3B cells were seeded in 6-well
plates at a density of 1 × 105 per well and infected with
Ad.SPDD, ZD55 or wild-type adenovirus at an MOI
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of 10. The cells were washed with PBS 3 times 8 hours
post-infection and fresh medium was added. All cells
and the culture medium were collected 48 hours post-
infection, and the adenoviruses were titered, after being
released by three freeze-thaw cycles. MRC-5 and Huh-7
cells with the indicated adenoviruses infected for 8
hours were also collected after washing with PBS for 3
times, the cells were titered after three freeze-thaw
cycles as a negative control to 48 hours’ infected cells.
Western blot assay
Cells were treated with different agents at an MOI of 10
and harvested at the indicated times. Western blot ana-
lysis was carried out according to standard procedures.
E1A-, caspase-3-, and actin-specific antibodies and sec-
ondary antibodies were obtained from Santa Cruz Bio-
technology (Santa Cruz, CA). Caspase-8- and caspase-9-
specific antibodies were purchased from Cell Signaling
Technology (Beverly, MA). The E1B 55kDa-specific anti-
body was purchased from Oncogene (Cambridge, MA),
the E1B 19kDa-specific antibody was purchased from
Calbiochem (San Diego, CA), and the Hexona-specific
antibody was obtained from Millipore (Billerica, MA).
Animal experiments
The animal experiments were conducted according to the
U.S. Public Health Service Policy on Humane Care and
the Use of Laboratory Animals. The experiments were
also approved by the Institutional Animal Care and Use
Committee. Four-week-old male BALB/c nude mice were
purchased from the Shanghai Experimental Animal Center
(Shanghai, China). A total of 8 × 106 Huh-7 cells was
injected subcutaneously in the right rear back of each
mouse to establish the xenograft tumor. When the tumor
size reached 100-150 mm3, the mice were randomly
divided into 4 groups and intratumorally injected with
adenovirus (5 × 108 PFU per mouse each time) or PBS
four times in the first 5 days, with no virus injected on the
third day. Subsequently, the lengths and widths of the
tumors were measured every four days. Tumor volume
(mm3) was calculated as length × (width)2/2.
Immunohistochemical analysis and TdT-mediated dUTP
nick end labeling assays
Tumor tissues were collected four days post-injection, fixed
in 4% formaldehyde overnight, and embedded in paraffin.
Subsequently, 5- μm-thick sections were cut and subjected
to H&E staining, immunohistochemistry and TdT-
mediated dUTP nick end labeling assay (TUNEL). The
expression of hexon and HCCS1 with an HA Tag were
detected separately using a goat anti-hexon (Chemicon)
and a rabbit anti-HA (Santa Cruz) antibody, respectively.
The immunohistochemistry assay was performed using the
rabbit or goat SP (HRP) staining system (Westang Biotech-
nology, Shanghai, China). The TUNEL assay was per-
formed according to the manufacturer’s instructions (R&D
systems).
Cytotoxicity assay
For the crystal violet staining, the cells were infected with
the various viruses at the indicated MOI. Four days later,
the cells were stained with 2% crystal violet in 20% metha-
nol for 1 h, then washed carefully and photographed.
For the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tet-
razolium bromide (MTT) assay, cells infected with
viruses at different MOI were cultured at 37°C for 4 d
after infection, then 20 μl of MTT solution (Sigma) was
added per well (5 mg/ml) and the cells were incubated at
37°C for 4 h. The supernatant was then removed, and
100 μl of 0.04 M HCl-isopropanol solution was added to
each well. Cell viability was measured by absorbance at
dual wavelengths (595 nm and 650 nm) using a Micro-
plate Reader (Bio-Rad). The viability of cells infected with
viruses at an MOI of 10 was detected in the same way on
days 1 to 4.
Hoechst33258 staining
Cells were infected with different viruses at an MOI of 10.
Forty-eight hours later, the cells were fixed with 4% paraf-
ormaldehyde, stained with Hoechst33258 (Molecular
Probes, Eugene, OR) at 1 μg/ml for 1 min, and then visua-
lized with a microscope.
Flow cytometric analysis
Cells were infected with various viruses at an MOI of 10,
and both adherent and suspended cells were collected 48
hours post-infection. Detection of apoptosis was per-
formed following the manufacturer’s instructions for the
Annexin V-FITC Apoptosis Detection kit (BioVision).
For analysis of the mitochondrial membrane potential,
the collected cells were stained with the JC-1 fluorescent
probe (Beyotime, Nantong, China) and analyzed using a
FACSCalibur flow cytometer.
Statistical analysis
All data were analyzed using Student’s t test or a one-way
analysis of variance (ANOVA) using the software R and
subsequently shown as the mean+SD. The P value results
are shown as P < 0.05:*, P < 0.01:**, or P < 0.001:*** in
the figures. A one-way ANOVA was performed using R
software when there were more than two groups in the
comparison analysis. The TukeyHSD command was also
used to comparatively assess the P values between two
independent groups. The survival curves were created in
Sigma plot, and the P values were calculated using
GraphPad Prism 5.0 using the log-rank test.
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Additional material
Additional file 1: Identification of the viruses at the DNA level. (A)
Blast sequence results for the region covering the deleted 24 bp of E1A
(B) Identification of the E1B region of the viruses in order to detect wild
type adenovirus contamination, by PCR amplification assay. Ad.WT and
ZD55 virus DNA were tested as positive controls. (C)-(E) PCR results of
positions at which the HCCS1 gene cassette, HCCS1 gene and SV40EAFP
promoter were inserted. pAd.SPDD-HCCS1HA was used as positive
control. pAd.SPDD was tested as negative control.
Additional file 2: HCCS1HA was specifically expressed in Huh-7
cells. MRC-5 and Huh-7 cells were infected with Ad.SPDD-HCCS1HA at
an MOI of 10. The cells were collected for western blot 48 hours post
infection. An anti-HA antibody was used to detect the expression of
HCCS1HA. Actin was used as a loading control.
Additional file 3: Ad.SPDD, ZD55, and Ad.WT exhibit similar
replicative ability in Hep3B cells. Hep3B cells were infected with Ad.
SPDD, ZD55, or Ad.WT at an MOI of 10. The adenoviral titers were
measured 48 hours post infection. (NS: not significant, p > 0.05)
List of abbreviations
Ad.SPDD: Ad.SP.E1A(Δ24).ΔE1B; HCCS1: Hepatocellular carcinoma suppressor
1; CTGVT: Cancer Targeting Gene-Viro-Therapy; CTGVT-LC: Cancer Targeting
Gene-Viro-Therapy Specific for Liver Cancer; AFP: α-fetoprotein; WPRE:
Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element; TUNEL:
TdT-mediated dUTP nick end labeling assay; and MTT: 3-(4, 5-
dimethylthiazol-2-yl)-2; 5-diphenyl tetrazolium bromide.
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